NIFTY  9,119.40  -0.19%
  SENSEX  29,365.30  -0.19%
 CURRENCY  Rs  64.61/$ 69.32/€, 82.81/£
  GOLD  29,384.00  0.30%
  SILVER  41,269.00  -0.57%
  DAX  12,048.60  0.18%
  FTSE  7,114.55  -0.06%
  CAC  5,059.20  -0.32%
  HANG SENG  24,042.00  -0.06%
  NIKKEI  18,620.80  1.03%
  Shanghai Composite  3,173.15  0.02%
  DOW JONES  20,547.80  -0.15%
  NASDAQ  5,910.52  -0.11%
  S&P 500  2,348.69  -0.30%
FROM ANI - Bank Of India Bulding Catches Fire In Fort Area, Mumbai SPICEJET - Launches Second Daily Direct Flight Between Kolkata-Dhaka

Merck, Cipla Avoiding Compulsory License?

Video:

Play this video

February 26: In a bid to skirt compulsory licenses issued by the Indian government, foreign drug makers are tying up with local partners to sign exclusive product licensing deals. The most recent instance seems of the agreement between Merck and Cipla to market the AIDS drug Raltegravir in India.